Current and future treatment options in SIADH

CKJ: Clinical Kidney Journal

Volumn 2, Issue SUPPL.3, 2009, Pages

  Zietse, Robert ^a   Van Der Lubbe, Nils ^a   Hoorn, Ewout J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

hyponatraemia; SIADH; urea; vasopressin; vasopressin receptor antagonist

Indexed keywords

EID: 84863695146     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp154     Document Type: Article

References (72)

1. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patientwith hyponatraemia: traditional versus physiology-based options. QJM 2005; 98: 529-540
2. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006; 119(Suppl 1): S36-S42
3. Gross P. Treatment of hyponatremia. Intern Med 2008; 47: 885-891
4. Feldman BJ, Rosenthal SM, Vargas GA et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352: 1884-1890
5. Fabian TJ, Amico JA, Kroboth PD et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004; 164: 327-332
6. Fenske W, Sẗork S, Blechschmidt A et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94: 123-129
7. Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49
8. Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J Physiol 1994; 267(Pt 2): R1617-R1625
9. Decaux G, Unger J, Brimioulle S et al. Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. JAMA 1982; 247: 471-474
10. Halperin ML, Kamel KS. A new look at an old problem: therapy of chronic hyponatremia. Nat Clin Pract Nephrol 2007; 3: 2-3
11. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-1589
12. Smith D, Moore K, Tormey W et al. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 2004; 287: E1019-E1023
13. McKenna K, Thompson C. Osmoregulation in clinical disorders of thirst appreciation. Clin Endocrinol (Oxf) 1998; 49: 139-152
14. Steele A, Gowrishankar M, Abrahamson S et al. Postoperative hyponatremia despite near-isotonic saline infusion: a phenomenon of desalination. Ann Intern Med 1997; 126: 20-25
15. Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. QJM 1998; 91: 749-753
16. Gross P, Reimann D, Neidel J et al. The treatment of severe hyponatremia. Kidney Int Suppl 1998; 64: S6-S11
17. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072
18. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003; 37: 1694-1702
19. Verbalis JG, Goldsmith SR, Greenberg A et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120(Suppl 1): S1-S21
20. Liamis G, Kalogirou M, Saugos V et al. Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant 2006; 21: 1564-1569
21. Mohmand HK, Issa D, Ahmad Z et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007; 2: 1110-1117
22. Hantman D, Rossier B, Zohlman R et al. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med 1973; 78: 870-875
23. Decaux G. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics. Nephron 1983; 35: 82-88
24. Perks WH, Walters EH, Tams IP et al.Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Thorax 1979; 34: 324-327
25. Cherrill DA, Stote RM, Birge JR et al. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975; 83: 654-656
26. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980; 243: 2513-2515
27. Curtis NJ, van Heyningen C, Turner JJ. Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing 2002; 31: 151-152
28. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009; 5: 193-202
29. Nielsen J, Hoffert JD, Knepper MA et al. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA 2008; 105: 3634-3639
30. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5: 270-276
31. Kazama I, Arata T, Michimata M et al. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats. Nephrol Dial Transplant 2007; 22: 68-76
32. Brodsky WA, Rapoport S. The mechanism of polyuria of diabetes insipidus in man; the effect of osmotic loading. J Clin Invest 1951; 30: 282-291
33. Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 2008; 19: 1076-1078
34. Decaux G, Prospert F, Penninckx R et al. 5-year treatment of the chronic syndrome of inappropriate secretion of ADH with oral urea. Nephron 1993; 63: 468-470
35. Van Reeth O, Decaux G. Rapid correction of hyponatraemia with urea may protect against brain damage in rats. Clin Sci (Lond) 1989; 77: 351-355
36. Soupart A, Schroeder B, Decaux G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrol Dial Transplant 2007; 22: 1856-1863
37. Verbalis JG, Baldwin EF, Neish PN et al. Effect of protein intake and urea on sodium excretion during inappropriate antidiuresis in rats. Metabolism 1988; 37: 46-54
38. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol 2008; 3: 1175-1184
39. Huang WY, Weng WC, Peng TI et al. Central pontine and extrapontine myelinolysis after rapid correction of hyponatremia by hemodialysis in a uremic patient. Ren Fail 2007; 29: 635-638
40. Ji DX, Gong DH, Xu B et al. Continuous veno-venous hemofiltration in the treatment of acute severe hyponatremia: a report of 11 cases. Int J Artif Organs 2007; 30: 176-180
41. Vanholder R,Van Biesen W, Lameire N. What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephrol 2001; 12(Suppl 17): S40-S43
42. Manning M, Lammek B, Kolodziejczyk AM et al. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to argininevasopressin. J Med Chem 1981; 24: 701-706
43. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112
44. Hoorn EJ, Zietse R. Tolvaptan for hyponatremia. N Engl J Med 2007; 356: 961; Author reply 962-963
45. Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91: 2145-2152
46. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331
47. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001; 110: 582-584
48. Saito T, Ishikawa S, Abe K et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82: 1054-1057
49. Soupart A, Gross P, Legros JJ et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1: 1154-1160
50. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009; 337: 28-36
51. Zeltser D, Rosansky S, van Rensburg H et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27: 447-457
52. Verbalis JG, Zeltser D, Smith N et al. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf) 2008; 69: 159-168
53. Palm C, Pistrosch F, Herbrig K et al. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006; 119(Suppl 1): S87-S92
54. Madias NE. Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia. Am J Kidney Dis 2007; 50: 184-187
55. Sterns RH, Cappuccio JD, Silver SM et al. Neurologic sequelae after treatment of severe hyponatremia: amulticenter perspective. J Am Soc Nephrol 1994; 4: 1522-1530
56. Lin SH, Hsu YJ, Chiu JS et al. Osmotic demyelination syndrome: a potentially avoidable disaster. QJM 2003; 96: 935-947
57. McGee S, Abernethy WB, Simel DL. The rational clinical examination. Is this patient hypovolemic? JAMA 1999; 281: 1022-1029
58. Sherlock M, O'Sullivan E, Agha A et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J 2009; 85: 171-175
59. Sonnenblick M, Algur N, Rosin A. Thiazide-induced hyponatremia and vasopressin release. Ann Intern Med 1989; 110: 751
60. Spital A. Diuretic-induced hyponatremia. Am J Nephrol 1999; 19: 447-452
61. Zeltser D, Rosansky S, van Rensburg H et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007; 27: 447-457
62. Goldsmith SR, Elkayam U, Haught WH et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008; 14: 641-647
63. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009; 337: 28-36
64. Wong F, Blei AT, Blendis LMet al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182-191
65. Gerbes AL, G̈ulberg V, Giǹes P et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized doubleblind multicenter trial. Gastroenterology 2003; 124: 933-939
66. Abraham WT, Shamshirsaz AA, McFann K et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47: 1615-1621
67. Saito T, Ishikawa S, Abe K et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82: 1054-1057
68. Inoue T, Ohnishi A, Matsuo A et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63: 561-570
69. Giǹes P, Wong F, Watson H et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204-213
70. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-2696
71. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-1971
72. Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545